Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the emerging ...

Roche’s new TAGS technology overcomes the technical limitations of a typical 4-plex test result in previous solutions, using a novel, proprietary approach. Without having to upgrade hardware or ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

BOSTON -- I can't recall the first time that I met Luis Tiant. But I can tell you that I was in awe when it happened. "El Tiante" was second only to Carl Yastrzemski when it came to Boston Red Sox ...

MANNHEIM, Germany, Oct 9 (Reuters) - Roche's (ROG.S), opens new tab experimental oral drug for breast cancer giredestrant could enter a market worth at least 10 billion Swiss francs ($12 billion ...

Brian Roche co-anchors News 8 at 5 p.m. each weekday. He is also the 8 On Your Side Consumer/Investigative reporter for News 8. Brian is an Emmy Award winning anchor and reporter. He has been ...

To get from Nice to Port-Fréjus, where Stephen Roche suggests we first meet, the motorway sweeps up and around the Cote d’Azur, bypassing familiar names such as Sainte-Maxime, St-Raphaël ...

A survey by Roche Diagnostics of 2,836 women aged 25 to 50 from eight Asia-Pacific countries discovered that 44 per cent of respondents delayed or avoided medical treatment because of familial ...

Répondant à l’invitation de la Chambre des métiers et de l’artisanat, Luc Bouard, maire de La Roche-sur-Yon (Vendée) et président de l’Agglo, s’est essayé au métier de boulanger le ...

Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...